Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Catalys Pacific is a venture capital firm focused on healthcare innovation, particularly in the biotech sector. Operating primarily in Japan and the United States, the firm seeks to improve patient lives through strategic investments. They emphasize a global network to identify unique opportunities in early-stage companies.
The firm invests in early-stage biotech companies within the healthcare sector, specifically during pre-seed, seed, and seed+ stages. Catalys Pacific prioritizes transpacific partnerships to enhance its investment strategy, targeting both outbound and inbound opportunities to maximize therapeutic impact for patients.
Notable projects include Mineralys, which focuses on hypertension control; Renalys, dedicated to novel therapies for Asian patients with renal disease; and Pathalys, aimed at providing new solutions for chronic kidney disease patients.
Submit your pitch through their website's contact form for consideration.
Yes, Catalys Pacific often leads investment rounds in the companies they back, particularly in early-stage biotech ventures.
The firm is open to follow-on investments, especially if the company demonstrates significant progress and potential for therapeutic impact.
Specific fund size details are not disclosed, but the firm actively seeks to invest in multiple early-stage biotech opportunities globally.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.